Aurora Cannabis: Buy, Sell or Hold?

Roth Capital Partners analyst Bill Kirk says Aurora Cannabis’ (Aurora Cannabis Stock Quote, Chart, News, Analysts, Financials TSX:ACB) fiscal Q1 results were largely in line, while guidance for sequential growth should ease some near-term uncertainty.

In an Aug. 6 update, Kirk reiterated his “Neutral” rating and $4.00 target on Aurora.

Aurora reported fiscal Q1 revenue of $67.6-million, in line with consensus at $67.5-million, while Adjusted EBITDA was $3.4-million, ahead of consensus at $2.4-million and slightly below Kirk’s $3.5-million estimate.

“Importantly, Aurora is guiding to 2Q revenue and adj. EBITDA growth, which should alleviate some uncertainty,” Kirk said. “Canadian Veteran reimbursement changes are offsetting underlying operational strength.”

Aurora’s adjusted gross margin was 58%, down from 60% in Q4 and 64% a year earlier. Kirk said the company’s gross margin remains a strength, reflecting its focus on high-quality medical cannabis and efficient production.

Management maintained its fiscal 2027 outlook, including revenue more in line with fiscal 2025 cannabis revenue, adjusted gross margin in the mid- to high-50% range and adjusted SG&A in line with fiscal 2026. Adjusted EBITDA is still expected to decline year-over-year, mainly because of Canadian reimbursement pricing changes.

Medical cannabis revenue fell 1.2% year-over-year, with 17.1% international growth offset by a 25.2% decline in Canada. Medical cannabis represented 95% of revenue and more than all gross profit in the quarter.

Kirk said Aurora continues to prioritize international medical opportunities over domestic adult-use sales, which supports its margin mix, though Canadian reimbursement changes remain a drag.

Consumer cannabis revenue fell 75% year-over-year and 42% sequentially.

Kirk said Aurora’s EU-GMP infrastructure at Ridge, River and Leuna, Germany gives it an advantage in growing international medical markets, including Australia, Germany, Poland, New Zealand and the United Kingdom.

For fiscal Q2, Kirk forecasts revenue of $72.2-million and Adjusted EBITDA of $5.1-million, unchanged from his previous estimates. For fiscal 2027, he now expects revenue of $297.7-million and Adjusted EBITDA of $22.7-million, down slightly from $299.5-million and $22.8-million.

“Sector sentiment and Aurora upside is still unjustifiably tied to U.S. regulatory change,” Kirk said.

The analyst said Aurora’s balance sheet is much improved and its gross margin structure remains among the strongest in Canadian cannabis. As added capacity helps meet unmet demand, he expects Aurora to resume growth.

 

-30-

Tagged with: acb
Rod Weatherbie

Rod Weatherbie is a journalist based in Prince Edward Island. Since 2004, he has written extensively about the Canadian property and casualty insurance landscape. He was also a founder and contributing editor for a Toronto-based arts website and a PEI-based food magazine. His fiction and poetry have been featured in The Fiddlehead, The Antigonish Review, and Juniper.

Recent Posts

NowVertical Group (TSXV:NOW) is a buy, this analyst says

NowVertical Group’s (NowVertical Group Stock Quote, Chart, News, Analysts, Financials TSXV:NOW) growing artificial intelligence business and recent $15.1-million financing could… [Read More]

3 hours ago

This analyst just raised his price target on Mattr Corp.

National Bank Financial analyst Nathan Po raised his target for Mattr Corp. (Mattr Corp. Stock Quote, Chart, News, Analysts, Financials… [Read More]

3 hours ago

AutoCanada wins price target raise at RBC

On Nov. 16, RBC Capital Markets analyst Sabahat Khan raised his target for AutoCanada (AutoCanada Stock Quote, Chart, News, Analysts,… [Read More]

4 hours ago

iFabric: Buy, Sell or Hold?

iFabric’s (iFabric Corp. Stock Quote, Chart, News, Analysts, Financials TSX:IFA) stronger-than-expected third-quarter results and growing recurring sales prompted Haywood Securities… [Read More]

4 hours ago

Can you make money with Metatek-Group stock?

Metatek-Group’s (Metatek-Group Stock Quote, Chart, News, Analysts, Financials TSX:MTEK) strong sequential revenue growth and expectations for a further improvement in… [Read More]

1 day ago

Ascend Wellness Holdings: Buy, Sell or Hold?

Ascend Wellness Holdings’ (Ascend Wellness Holdings Stock Quote, Chart, News, Analysts, Financials CSE:AAWH.U) return to year-over-year revenue growth and improving… [Read More]

1 day ago